Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. [electronic resource]
Producer: 20110103Description: 346-53 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Boronic Acids -- administration & dosage
- Bortezomib
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Hematologic Diseases -- chemically induced
- Humans
- Lymphoma, Follicular -- drug therapy
- Lymphoma, Mantle-Cell -- drug therapy
- Lymphoproliferative Disorders -- drug therapy
- Male
- Middle Aged
- Pyrazines -- administration & dosage
- Rituximab
- Survival Analysis
- Treatment Outcome
- Waldenstrom Macroglobulinemia -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.